| ID Source | ID |
|---|---|
| PubMed CID | 3080578 |
| CHEBI ID | 48742 |
| MeSH ID | M0083306 |
| Synonym |
|---|
| 3,7,12,24-tetrahydroxycholestanoic acid |
| tthca |
| cholestan-26-oic acid, 3,7,12,24-tetrahydroxy-, (3alpha,5beta,7alpha,12alpha)- (van) |
| 1061-64-9 |
| LMST04030067 |
| 3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid |
| varanic acid |
| CHEBI:48742 |
| 3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestanoic acid |
| 3alpha,7alpha,12alpha,24xi-tetrahydroxy-5beta-cholestan-26-oic acid |
| (3a,5b,7a,12a)-3,7,12,24-tetrahydroxy-cholestan-26-oic acid |
| Q27121366 |
| (6r)-3-hydroxy-2-methyl-6-((3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)heptanoic acid |
| DTXSID901318051 |
| Role | Description |
|---|---|
| bile acid metabolite | Metabolites of bile acids, four-ringed steroid acids formed along the cholesterol degradation pathway. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 3alpha-hydroxy steroid | A 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position. |
| 7alpha-hydroxy steroid | A 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration. |
| 12alpha-hydroxy steroid | |
| 24-hydroxy steroid | |
| hydroxy monocarboxylic acid | Any monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (9.09%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||